Usefulness of meta-[i]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment

Nuclear Medicine Communications

Volumn 26, Issue 2, 2005, Pages 97-102

  Fujimoto, Shinichiro ^a   Inoue, Aritomo ^a   Hisatake, Shinji ^a   Yamashina, Shohei ^a   Yamashina, Hisayo ^a   Nakano, Hajime ^a   Yamazaki, Junichi ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta blocker; Dilated cardiomyopathy; Long term prognosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NITRATE; SPIRONOLACTONE; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART SCINTISCANNING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; HOSPITALIZATION; JAPAN; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; PREVALENCE; PROGNOSIS; SCINTISCANNING; SURVIVAL; VALIDATION STUDY;

3-IODOBENZYLGUANIDINE; ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIA; CARDIOMYOPATHY, DILATED; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 13944259796     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200502000-00003     Document Type: Article

References (26)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355.
2. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
3. The cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
4. Redfield MM, Gersh BJ, Bailey KR, Rudeheter RJ. Natural history of incidentally discovered, asymptomatic idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 74:737-739.
5. McDermott MM, Feinglass J, Lee PI, Mehta S, Schmitt B, Lefevre F, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997; 134:728-736.
6. Wieland DM, Brown LE, Rogers L, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22:22-31.
7. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wielamd DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28:1625-1636.
8. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471-477.
9. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by metaiodobenzylguanidine in patients with failing and non-failing hearts. J Nucl Cardiol 1998; 5:579-590.
10. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, on behalf of the Ehime MIBG heart failure study investigators. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 2001; 65:155-160.
11. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40:917-923.
12. Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997; 133:353-358.
13. 123I-meta-iodobenzylguanidine imaging in predicting the effectiveness of β-blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 1999; 81:148-152.
14. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of β-blocker therapy in patients with dilated cardiomyopathy-clinical meaning of iodine-123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141:645-652.
15. 123I-MIBG in the failing human heart. J Nucl Med 1999; 40:224-231.
16. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999; 40:217-223.
17. 123I-MIBG scintigraphy study. J Nucl Med 2000; 41:845-851.
18. 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001; 42:49-54.
19. 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of β-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 2004; 31:1356-1361.
20. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, et al., for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468-1475.
21. Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G, for the V-HEFT VA Cooperative Studies Group. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. Circulation 1993; 87(suppl VI):24-31.
22. Cohn JN, Jihnson GR, Kay HR. Clinical determinations of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Circulation 1993; 87(suppl IV):15-16.
23. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93:1667-1676.
24. Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, et al. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histrogic viewpoint. J Am Coll Cardiol 1993; 21:628-633.
25. Merta M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003; 145:292-299.
26. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:574-581.